Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq data of ginsenoside Rg3-treated BGC823 gastric cancer cells

ABSTRACT: This study aims to explore the potential mechanism of Ginsenoside Rg3 against gastric cancer,we first found that the anti-GC cell proliferation by Rg3 in part is via inhibiting the formation of E2F-DP heterodimers, and suppressing the p53-p21-cyclin/CDKs-RB signaling pathway. These find-ings highlight the potential of Rg3 as a natural product with low toxicity and anti-tumor activity in cancer treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE275773 | GEO | 2025/09/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

Project description:The angio-suppressive effect of 20(R)-ginsenoside Rg3 (Rg3-R) has been previously demonstrated, and microRNAs (miRNAs) are a vital group of small non-coding RNAs that function as post-transcriptional modulator of gene expression. Thus, using human umbilical vein endothelial cells (HUVEC) as model, we compared the microRNA (miRNA) expression profile of vascular endothelial growth factor (VEGF)-induced cells with the profile of the cell co-treated with VEGF and Rg3-R. Among the screened 553 human miRNAs, 6 up-regulated (miR-520h, miR-487b, miR-197, miR-524*, miR-342 and miR-219) and 3 down-regulated (miR-23a, miR-489 and miR-377) miRNAs were detected in Rg3-R treated vascular endothelial growth factor (VEGF)-induced HUVECs compared to VEGF alone. Real time RT-PCR was subsequently performed to verify the miRNA microarray result. Two condition experiment: VEGF-induced HUVEC and VEGF-induced HUVEC treated with Rg3-R. Three independent microarray experiments, with triplicate per microarray.

2011-09-09 | E-GEOD-31959 | biostudies-arrayexpress

lncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

Project description:Ginsenoside 20(S)-Rg3, an active saponin monomer extracted from red ginseng, inhibits the malignancy of ovarian cancer cells. RNA-Seq analysis was used for deep sequencing of lncRNA to detected molecular mechanisms of 20(S)-Rg3.We identified 85 differentially expressed lncRNA influenced by 20(S)-Rg3, among which 67 lncRNAs were significantly decreased (fold change<0.5, p<0.05) including 12 ncRNAs and 55 pseudo genes, and 18 lncRNAs were significantly increased (fold change>1.5, p<0.05) including 3 ncRNAs, 14 pseudo genes and 1 unknown gene. This study provide a valuable resource for the discovery of lncRNAs related to anti-tumor mechanism of 20(S)-Rg3.

2021-02-16 | GSE118216 | GEO

MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

2011-09-10 | GSE31959 | GEO

Phosphoproteomics analysis of anti-cancer effects of ginsenoside Rg3 in human breast cancer cells

Project description:The breast cancer incidence has been increasing in China, with the earlier age of onset compared with Western countries. Traditional Chinese medicine has been provided as one of the major source of anti-cancer drugs. Ginseng is one of the most common traditional medicines in China. Ginsenosides, the saponins in the plant Panax (ginseng) are the major active components responsible for their chemopreventive effects from cancer. However, the mechanisms by which ginsenosides exert their anti-cancer effect remain elusive. By combining TMT-based quantitation with TiO2-based phosphopeptide enrichment, we performed a quantitative analysis of the changes of the phosphoproteomes in ginsenoside Rg3-treated breast cancer MDA-MB-231 cells. We were able to quantitate 5,140 phosphorylation sites on 2,041 phosphoproteins. Our data show that the phosphorylation status of 13 sites was changed in MDA-MB-231 cells upon Rg3 treatment. The perturbed phosphoproteins are CPSF7, EEF2, HIRIP3, MAGED2, MPRIP, MYCBP2, PAWR, PPP1R12A, RANBP2, SEPT9, TMPO, and UFL1. These proteins are involved in various biological processes, including protein synthesis, cell division, and inhibition of NF-κB signaling. Our study revealed that Rg3 exerts its anti-cancer effects through a combination of different signaling pathways.

2018-01-08 | PXD003092 | Pride

Ginsenoside Rg3 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of the MCF-7 breast cancer cell

Project description:Genome wide DNA methylation profiling of estrogene receptor postive breast cancer cell line MCF-7, treating Ginsoenoside Rg3. The Illumina Infinium Human Methylation EPIC v1.0 B2 Bead chip was used to obtain DNA methylation profiles across approximately 850,000 CpGs. This profiling indicates that Ginsenoside Rg3 induces epigenetic and cellular changes.

2017-12-31 | GSE99505 | GEO

Ginsenoside Rg3 Reduces the Toxicity of Graphene Oxide Used for pH-Responsive Delivery of Doxorubicin to Liver and Breast Cancer Cells

Project description:RNA sequencing experiments revealed that the killing effect of the GO-Rg3-DOX nanoplatform proceeds primarily by downregulation of anti-apoptotic and angiogenesis related genes

2023-02-27 | GSE185139 | GEO

lncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

Project description:lncRNA sequencing of human ovarian cancer cell SKOV3 after exposure to ginsenoside 20(S)-Rg3

| PRJNA484884 | ENA

A systematic exploration on Ginsenoside Rg5 reveals proresolving functions in airway mucous cells.

Project description:Ginsenoside Rg5 reveals proresolving functions in airway mucous cells through inhibition of ROS production and promoting anti-inflammation factors

2023-01-25 | GSE173990 | GEO

Homo sapiens

Project description:MicroRNAs expression in 20(R)-ginsenoside Rg3-induced anti-angiogenesis

| PRJNA144995 | ENA

Ginsenoside Rg3 Reduces the Toxicity of Graphene Oxide Used for pH-Responsive Delivery of Doxorubicin to Liver and Breast Cancer Cells

Project description:Ginsenoside Rg3 Reduces the Toxicity of Graphene Oxide Used for pH-Responsive Delivery of Doxorubicin to Liver and Breast Cancer Cells

| PRJNA767790 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data